Oral Hypoglycemic Agent Update

Krall, Leo P.; Chabot, V.

doi:10.1016/s0025-7125(16)31765-5

Cited by 13 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These compounds are active in mild streptozotocininduced diabetes whereas they are inactive in intense streptozotocin diabetes (nearly all β-cells have been destroyed). Since our results showed that glibenclamide reduced blood glucose levels in hyperglycemic animals, the state of diabetes is not severe 35,36 . Streptozotocin-treated animals receiving the leaf extract of B. diffusa showed rapid normalization of blood glucose levels in comparison to control and this could be due to the possibility that some β-cells were still active and were acted upon by B. diffusa to exert their insulin releasing effect.…”

Section: Resultsmentioning

confidence: 58%

Effect of chronic administration of <i>Boerhaavia diffusa</i> Linn. leaf extract on experimental diabetes in rats

Nalamolu¹,

Boini²,

Nammi³

2007

Trop. J. Pharm Res

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 58%

Effect of chronic administration of <i>Boerhaavia diffusa</i> Linn. leaf extract on experimental diabetes in rats

Nalamolu¹,

Boini²,

Nammi³

2007

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…The experimental values for these properties were obtained from different bibliographic sources − (Table ).…”

Section: Methodsmentioning

confidence: 99%

QSAR Analysis of Hypoglycemic Agents Using the Topological Indices

Murcia-Soler

Pérez-Giménez

Nalda-Molina

et al. 2001

J. Chem. Inf. Comput. Sci.

View full text Add to dashboard Cite

The molecular topology model and discriminant analysis have been applied to the prediction of some pharmacological properties of hypoglycemic drugs using multiple regression equations with their statistical parameters. Regression analysis showed that the molecular topology model predicts these properties. The corresponding stability (cross-validation) studies performed on the selected prediction models confirmed the goodness of the fits. The method used for hypoglycemic activity selection was a linear discriminant analysis (LDA). We make use of the pharmacological distribution diagrams (PDDs) as a visualizing technique for the identification and selection of new hypoglycemic agents, and we tested on rats the predictive ability of the model.

show abstract

“…In 1970 it was suggested in a report from the University Group Diabetes Program that oral antidiabetic treatment with tolbutamide resulted in a significantly higher death rate from cardiovascular disease than dietary treated patients. However, these findings have not been generally accepted and are not confirmed by later studies (Krall and Chabot, 1978).…”

Section: Diabetes Mellitusmentioning

confidence: 71%

Secondary prevention after myocardial infarction: Subgroup analysis of patients at risk in the norwegian timolol multicenter study

Gundersen¹

1985

Clinical Cardiology

View full text Add to dashboard Cite

Timolol treatment after myocardial infarction is generally related to a significant reduction in both morality and reinfarction compared with placebo. Retrospective analyses of the timolol study are performed on subgroups of patients with a high placebo mortality. The present study shows that these patients are target groups for secondary prevention, as they benefit most from timolol treatment after myocardial infarction. In patients 65‐75 years of age, the number of cardiac deaths and reinfarctions prevented by timolol treatment is twice as high as that of patients below 65 years of age. Timolol treatment is well tolerated in the older age group and the contraindications for timolol treatment are independent of age up to 75 years. The reduction in mortality and reinfarction is independent of heart size at baseline. However, in patients with cardiomegaly and compensated heart failure on treatment with digitalis and diuretics, timolol treatment may be of special importance because of the very high incidence of cardiac death in this group of patients. In patients with compensated heart failure on treatment with digitalis and diuretics, timolol treatment does not precipitate heart failure. Patients with stable diabetes mellitus basically behave like nondiabetic patients regarding inclusion rate, side effects, and timolol‐related reduction in mortality and reinfarction. Decisions concerning secondary prevention with timolol should be independent of preinfarction and postinfarction angina. In conclusion, 70‐80% of all the patients below 75 years of age surviving myocardial infarction, without contraindication to betablocker treatment, can be treated with timolol 10 mg twice daily to reduce mortality and reinfarction. In contrast to previous routines, secondary prevention with beta blockers should be especially directed to high‐risk patients.

show abstract

Oral Hypoglycemic Agent Update

Cited by 13 publications

References 44 publications

Effect of chronic administration of <i>Boerhaavia diffusa</i> Linn. leaf extract on experimental diabetes in rats

Effect of chronic administration of <i>Boerhaavia diffusa</i> Linn. leaf extract on experimental diabetes in rats

QSAR Analysis of Hypoglycemic Agents Using the Topological Indices

Secondary prevention after myocardial infarction: Subgroup analysis of patients at risk in the norwegian timolol multicenter study

Contact Info

Product

Resources

About